CHMP recommends licence extension for durvalumab (Imfinzi)

Durvalumab is intended to be licensed for use, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adults with extensive-stage small cell lung cancer.

European Medicines Agency